ClinicaliQ Trial Snapshot
- Less Invasive Surfactant Administration in Late Preterm or Early Term Born Infants — Recruiting • Non-phase study • Respiratory / COPD / Asthma • NCT06421506.
- What is being tested: Less invasive surfactant administration (LISA) delivered via a thin catheter during high-flow nasal cannula therapy, compared to standard care, to reduce the need for intubation and mechanical ventilation in preterm infants with respiratory distress.
- Patient eligibility overview: Late preterm or early term infants (born 2-6 weeks early) experiencing breathing difficulties who require oxygen support, representing a cohort between extremely preterm and term-born populations.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The aim of this study is to see if giving less invasive surfactant administration (LISA) during high-flow nasal cannula (HFNC) oxygen treatment reduces the need for invasive ventilation in babies with breathing problems born 2-6 weeks early. Less invasive surfactant administration is where surfactant (a naturally produced substance which helps open up the tiny air sacs in the lungs making it easier for babies to breathe) is given into the lungs by putting a small tube into the windpipe through the mouth whilst the baby is awake. The surfactant is…
Eligibility Snapshot
- : * Infants born at 34+0 to 38+6 weeks of gestation, requiring resuscitation at birth, but who achieve regular spontaneous breathing and have a heart rate over 100 beats per minute while receiving non-invasive support. * Infants enrolled in the Surfon trial, born at 34+0 to 38+6 weeks of gestation, who are less than or equal to 24 hours old and exhibit signs of respiratory distress, defined as an FiO2 greater or equal to 0.30 but less than 0.45 needed to maintain an SpO2 greater than or equal to 92% or a clinically significant work of breathing regardless of the FiO2 and a clinical decision to provide non-invasive respiratory support.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.